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Abstract
Background: Intraoperative dexmedetomidine may decrease postoperative emergence agitation in elderly patients
due to its sedative effect. In this study, we evaluated the effect of adjuvant dexmedetomidine on smooth emergence
from anaesthesia after orthopaedic surgery in elderly patients.
Methods: A total 115 patients (ASA I–II, aged over 65 years) were randomly allocated into four groups. Anaesthesia
was maintained with either sevoflurane or total intravenous anaesthesia (TIVA) comprising propofol and remifentanil.
Patients were also administered either dexmedetomidine (0.4 μg kg−1 hr−1; SD and TD) intraoperatively or normal
saline (SN or TN) as a control. The bispectral index (BIS) score was maintained from 40–60 intraoperatively. All
anaesthetics and dexmedetomidine were discontinued at surgical conclusion, and the recovery times (durations to
a BIS = 60, 70, and 80; eye opening; and extubation) were measured. The mean arterial pressure, heart rate, Ricker’s
agitation-sedation scale (RSAS), visual analogue scale (VAS) for pain, and incidences of emergence agitation and
postoperative nausea and vomiting (PONV) were measured in the recovery room.
Results: Dexmedetomidine significantly decreased the RSAS score in the SD and TD groups, and a calm state
postoperatively occurred more frequently in these groups than in the control groups. The heart rate and incidence of
emergence agitation were lower in the dexmedetomidine groups. Recovery time was higher in the SD group than in
the SN group, and no significant differences occurred between the TN and TD groups. The VAS score was lower in the
SD group than in the SN group, and the PONV did not differ regardless of the use of dexmedetomidine.
Conclusions: Dexmedetomidine may be an effective intraoperative adjuvant for a reducing emergence agitation and
smooth emergence from anaesthesia after orthopaedic surgery in elderly patients.
Trial registration: Current Controlled Trials NCT01851005.
Keywords: Dexmedetomidine, Emergence agitation, Ricker’s agitation-sedation scale, Sevoflurane, Total intravenous
anaesthesia
Background
As the elderly population continues to increase, surgery
of elderly patients is also on the rise. The risk of postop-
erative complications during recovery such as emergence
agitation or delirium in the elderly is also increasing [1].
Emergence agitation/delirium, which have been used
interchangeably in most of the literature [2], defined as a
state of mild restlessness and mental distress and a rest-
less or confused status after emergence from anaesthesia
[2, 3]. This can be dangerous due to harmful behaviours
by the patients such as injury, haemorrhage, and self-
extubation [3]. The incidence of delirium in the elderly
is highest after major orthopaedic surgery [4]. A recent
study showed that dexmedetomidine reduced the inci-
dence of emergence agitation in children after sevoflur-
ane anaesthesia [5], and another study found that
intraoperative adjuvant dexmedetomidine can improve
the stability of recovery from anaesthesia [6]. Thus, in
the present study, we investigated the effect of adjuvant
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dexmedetomidine on emergence from anaesthesia under-
going elective orthopaedic surgery recovery in elderly pa-
tients targeting smooth emergence.
Methods
This study was approved by the Internal Review Board
(IRB) of Chosun University Hospital and the Korean
Food & Drug Administration (KFDA, 20130039565),
and was registered at http://clinicaltrials.gov (registration
number NCT01851005).
A total 115 patients at ASA class I-II, aged over
65 years, and scheduled for elective orthopaedic surgery
were enrolled. Patients with the following conditions
were excluded: severe heart disease with a New York
Heart Association class > III, severe arrhythmia, uncon-
trolled hypertension or hypotension, hemodynamic in-
stability, drug hypersensitivity, any cognitive deficiency,
hepatic or renal compromise, infectious disease, and sur-
gery lasting more than 3 h. Written informed consent
was obtained from all patients after full explanation of
the study.
Patients were randomly allocated into two groups ac-
cording to anaesthetic method (sevoflurane or total intra-
venous anaesthesia, TIVA) using computer-generated
random numbers. They were allocated again into four
groups according to the use of dexmedetomidine. In the
SN group (n = 28) and SD group (n = 27), anaesthesia was
maintained with sevoflurane and a 50 % O2-air mixture.
In the TN (n = 30) and TD (n = 30) groups, anaesthesia
was maintained TIVA comprising propofol and remifenta-
nil. In the SD and TD groups which were the experimen-
tal group, dexmedetomidine (Precedex® 100 mg/ml,
Hospira, Inc., Rocky Mount, IL, USA) was administered at
0.4 μg kg−1 hr−1 after aesthetic induction until surgical
conclusion [6]. Normal saline was administered at the
same rate (0.1 ml kg−1 hr−1) as a control in the SN and
TN groups which were the control group. Adjuvant drug
was prepared by an independent nurse who was not in-
volved in the management of the patients. Dexmedetomi-
dine was diluted to a 50-ml volume, normal saline was
prepared in a 50-ml syringe, and each drug was labelled as
coded syringes. Thus, the anaesthesiologist and nurses
who participated in anaesthesia and recovery were blinded
to the adjuvant drugs.
All patients were administered midazolam (0.05 mg kg−1,
intramuscularly) as a premedication 30 min before anaes-
thesia. Upon arrival to the surgical suite, the electrocardio-
gram (ECG), pulse oximetry for oxygen saturation (SpO2),
non-invasive arterial pressure (NIBP), and bispectral index
(BIS) (BIS monitor A-2000; Aspect Medical Systems,
Norwood, MA, USA) were monitored. Anaesthesia was in-
duced according to the following protocols. In the SN
and SD groups, anaesthesia was induced with propo-
fol at 1.5–2.0 mg kg−1 and manual mask ventilation
was done with 3–4 vol% sevoflurane and 50 % O2-air
mixture until adequate neuromuscular blocking was
achieved. In the TN and TD groups, anaesthesia was
induced with remifentanil and propofol based on a
Minto and Marsh pharmacokinetic model using a TCI de-
vice (Orchestra® Base Primea, Fresenius-Vial, France). The
targeted effect-site concentrations (Ce) of propofol and
remifentanil for induction were 3 μg/ml and 2.5 ng/ml,
respectively. Once the patient lost consciousness, rocuro-
nium was administered at 1.0 mg kg−1 and endotracheal
intubation was performed. During mechanical ventilation,
the initial tidal volume was set at 8 ml/kg, and the tidal
volume and frequency were adjusted to maintain the end-
tidal CO2 between 4.6 and 5.3 kPa. Anaesthesia was main-
tained with sevoflurane or propofol-remifentanil and a
50 % O2-air mixture. During the maintenance of anaesthe-
sia, the end-tidal concentration of sevoflurane and the Ce
of propofol and remifentanil were adjusted to maintain
the BIS score near 50 (range 40–60) and maintain the vital
signs within 20 % of their baseline values. Those values
were recorded before administrating the adjuvant drugs
and at 5 min, 10 min, 15 min, 30 min, 60 min, and
120 min after infusion.
After anaesthetic induction, the adjuvant drugs (dexme-
detomidine or normal saline) were infused. The mean arter-
ial pressure (MAP) and heart rate (HR) were measured
before administering the adjuvant drugs, 10 min and
30 min after infusion of adjuvant drugs, upon arrival in the
recovery room, 15 min after arrival in the recovery room,
and 30 min after arrival in the recovery room. When
bradycardia (HR < 40 bpm), tachycardia (HR > 110 bpm),
hypertension (MAP > 110 mmHg), or hypotension
(MAP < 60 mmHg) were observed, atropine 0.5 mg,
esmolol 10 mg, nicardipine 0.5 mg, ephedrine 5 mg,
or phenylephrine 100 μg was administered as treat-
ment, respectively.
At the end of surgery, fentanyl administration was
started using patient controlled anaelgesia instrument
(initial loading 0.9 μg kg−1; basal infusion, 0.625 μg kg−1
hr−1; intermittent bolus, 0.9 μg kg−1 hr−1; lockout time,
30 min) according to the hospital protocol before ad-
ministration of reversal agents. Reversal agents (glyco-
pyrrolate 0.004 mg kg−1 and neostigmine 0.02 mg kg−1)
were administered, and the recovery from the neuro-
muscular block was confirmed using a train-of-four ra-
tio. Administration of all anaesthetics and adjuvant
drugs was discontinued, and disturbance or stimulation
of the patients was avoided, except a verbal request to
open their eyes. When the patients could breathe spon-
taneously, follow the command to open their eyes, and
had a BIS score greater than 80, they were extubated
and transferred to the recovery room. The recovery
times were measured as follows: the duration from dis-
continuing all drugs to achieving a BIS score of 60, 70,
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and 80; the duration in minutes until the patients
responded to the command of eye opening; and the
duration to extubation [7, 8].
The patients were transferred to the recovery room,
and the BP, HR, 11-point visual analogue scale for pain
(0 = no pain and 10 = worst pain imaginable), and the
Riker’s sedation-agitated scale (RSAS) were measured.
The RSAS was measured three times at 15-min intervals
according to the following scale: 1 =minimal or no re-
sponse to noxious stimuli; 2 = arousal to physical stimuli
but noncommunicative; 3 = difficult to arouse but
awakens to verbal stimuli or gentle shaking; 4 = calm
and follows commands; 5 = anxious or physically agi-
tated but calms to verbal instructions; 6 = requires re-
straint and frequent verbal reminding of limits; and 7 =
attempting to remove tracheal tube or catheters, or
striking at staff [9]. Patients were classified according to
the RSAS score (anxious or agitated, RSAS 5 to 7; calm,
RSAS 4; and sedated, RSAS 1 to 3) [9]. Each patient’s
maximum RSAS score, and the incidences of emergence
agitation (scale ≥5) and dangerous EA (score = 7) were
recorded [3, 6, 9]. The pain score was measured using
the visual analogue scale (VAS) in the recovery room.
The incidence of postoperative nausea and vomiting
(PONV) was also measured by asking the presence of
PONV to the patients. The duration of hospitalization in
the recovery room was also measured.
Statistical analysis
Sample size was calculated using “G*Power3” free soft-
ware (available at: http://www.psycho.uni-duesseldorf.de/
abteilungen/aap/gpower3). The effect size was 0.329,
which was calculated based on a previous study in which
the incidence of emergence agitation decreased from 52
to 28 % after dexmedetomidine infusion [6]. Using α =
0.05 with a power of 80 %, the total sample size was cal-
culated at 108. After assuming a 10 % drop out rate, 30
patients were allocated to each group.
Statistical analyses were performed using SPSS 12.0
(SPSS, Inc., Chicago, IL, USA). The normality of distri-
bution was assessed with the Kolmogorov-Smirnov test.
Values are expressed as the mean (SD) or the number of
patients (%). Parametric data (weight, recovery time,
maximum RSAS score, and VAS) were analysed with the
one-way ANOVA test; the Mann–Whitney U-test was
used for post-hoc analysis. Non-parametric data (age,
height, duration of surgery, duration of recovery room
stay) were analysed using the Kruskal Wallis test. Cat-
egorical variables (gender, ASA class, type of surgery,
and incidences of EA and PONV) were analysed by the
Chi-square or Fisher’s exact test. A P < 0.0125 was con-
sidered statistically significant, accounting for a Bonferroni
correction in comparison of four groups and a P < 0.05
was considered statistically significant in comparison of
experimental groups and control groups. The change in
the end-tidal concentration of sevoflurane and the Ce of
propofol and remifentanil were analysed by repeated mea-
sures ANOVA, and post-hoc testing was performed using
the turkey and t-test. A P < 0.05 was considered statisti-
cally significant between two groups.
Results
A total 141 patients were assessed for eligibility, and 120
patients were enrolled. Two patients in the SN group
and one patient in the SD group were excluded because
the surgery lasted more than 180 min. One patient in
the SD group was excluded because of reoperation due
to postoperative haemorrhage. Finally, 115 patients were
analysed (Fig. 1).
There were no significant differences in the characteris-
tic data, type of surgery, and duration of surgery between
the groups (Table 1). During anaesthetic maintenance, the
end-tidal concentration of sevoflurane was lower in the
SD group than in the SN group at 10 min after adminis-
tering dexmedetomidine (P < 0.05, Fig. 2a). The Ce of pro-
pofol in the TD group was less than that in the TN group
at 10 min after administering dexmedetomidine (P < 0.05,
Fig. 2b). However, the Ce of remifentanil did not show any
significant differences between the TS and TD groups
(P > 0.05, Fig. 2c).
Recovery times are presented in Fig. 3. The duration to
eye opening and extubation were longer in the SD group
compared to those in the SN group (10.0 min vs.
13.8 min, and 11.7 min vs. 15.7 min, P = 0.001 and 0.004,
respectively). However, there were no significant differ-
ences in the recovery times between the TIVA groups re-
gardless of whether dexmedetomidine was used.
The maximum RSAS score differed significantly be-
tween the groups (P < 0.001, Table 3). The maximum
scores were lower in the experimental groups compared
to the control groups (5.4 ± 1.0 in group SN vs. 4.1 ± 0.3
in group SD, P < 0.001; 4.9 ± 1.2 in group TN vs. 4.2 ±
0.7 in group TD, P = 0.021). Patients were also catego-
rized after arrival to the recovery room according to the
RSAS (Table 2). Patients who were administered dexme-
detomidine maintained RSAS score less than 5 (40.7 %
in group SN vs. 25 % in group SD, P < 0.001; 36.7 % in
group TN vs. 53.3 % in group TD, P = 0.013) lasting
until 15 min into recovery (71.4 % in group SN vs.
88.9 % in group SD, P = 0.013; 66.7 % in group TN vs.
90 % in group TD, P = 0.021). Patients administered dex-
medetomidine showed a lower incidence of emergence
agitation compared to the control patients (P < 0.001).
The incidence of emergence agitation was 11.1 % and
10.0 % in the SD and TD groups, and 75.0 and
43.3 % in the SN and TN groups, respectively. The
incidences of dangerous emergence did not differ be-
tween the groups (Fig. 4).
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Age (yr) 0.587 72.3 (6.2) 72.6 (4.3) 0.066 73.5 (7.2) 74.5 (6.5) 0.884
Gender (M/F) 0.977 8/20 9/19 0.873 8/22 10/20 0.791
Height (cm) 0.547 156.3 (8.4) 158.8 (7.5) 0.888 156.9 (7.8) 158.5 (9.0) 0.301
Weight (kg) 0.895 58.3 (8.2) 58.0 (9.7) 0.368 56.7 (10.4) 58.4 (11.2) 0.844
ASA class (I/II) 0.115 8/20 4/23 0.217 11/19 13/17 0.598
Type of surgery 0.656 0.747 0.980
Total hip replacement 4 (14.3) 2 (7.4) 4 (13.3) 4 (13.3)
Total knee replacement 7 (25) 5 (18.5) 3 (10) 4 (13.3)
Long bone fracture fixation 6 (21.4) 7 (25.9) 13 (43.3) 12 (40)
Spinal surgery 11 (39.3) 14 (48.1) 10 (33.3) 10 (33.3)
Duration of surgery (min) 0.717 116.7 (29.7) 115.7 (29.6) 0.684 115.3 (39.1) 107.0 (34.6) 0.386
Values are the mean (SD) or number (%). Group SN, inhalation anaesthesia using sevoflurane and normal saline administered as a control; Group SD, inhalation
anaesthesia using sevoflurane and adjuvant dexmedetomidine; Group TN, TIVA using propofol and remifentanil and normal saline administered as a control;
Group TD, TIVA using propofol and remifentanil, and adjuvant dexmedetomidine; TIVA total intravenous anaesthesia, SD standard deviation
Fig. 1 Consort flow diagram for the study. Group SN, inhalation anaesthesia using sevoflurane and normal saline administered as a control;
Group SD, inhalation anaesthesia using sevoflurane and adjuvant dexmedetomidine; Group TN, TIVA using propofol and remifentanil and
normal saline administered as a control; Group TD, TIVA using propofol and remifentanil, and adjuvant dexmedetomidine
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Fig. 2 (See legend on next page.)
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There were no significant differences in MAP during
infusion of adjuvant drugs and between the dexmedeto-
midine and control groups (P > 0.05, Fig. 5). The HR was
lower in the SD group compared to that in the SN group
15 min after the patients arrived in the recovery room.
The HR was also lower in the TD group TD compared
to that in the TN group 30 min after arrival to the re-
covery room.
The VAS score at the recovery room in the SD group
was less than that in the SN group (P = 0.011), however,
(See figure on previous page.)
Fig. 2 End-tidal concentration of sevoflurane (a), the effect site concentration of propofol (b), and the effect site concentration of remifentanil (c)
during anaesthesia. Group SN, inhalation anaesthesia using sevoflurane and normal saline administered as a control; Group SD, inhalation
anaesthesia using sevoflurane and adjuvant dexmedetomidine; Group TN, TIVA using propofol and remifentanil and normal saline administered
as a control; Group TD, TIVA using propofol and remifentanil, and adjuvant dexmedetomidine; TIVA, total intravenous anaesthesia; Ce, effect site
concentration. *P < 0.05 compared with the control group
Fig. 3 Recovery times following orthopaedic surgery. Group SN, inhalation anaesthesia using sevoflurane and normal saline administered as a
control; Group SD, inhalation anaesthesia using sevoflurane and adjuvant dexmedetomidine; Group TN, TIVA using propofol and remifentanil and
normal saline administered as a control; Group TD, TIVA using propofol and remifentanil, and adjuvant dexmedetomidine; TIVA, total intravenous
anaesthesia; BIS, bispectral index. *P < 0.05 compared with SN
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At arrival Sedated <0.001 1 (3.6) 13 (48.1) <0.001 6 (20.0) 11 (36.7) 0.013
Calm 7 (25.0) 11 (40.7) 11 (36.7) 13 (53.3)
Agitated 20 (71.4) 3 (11.1) 16 (43.3) 3 (10.0)
After 15 min Sedated 0.005 0 (0.0) 2 (7.4) 0.013 0 (0.0) 1 (3.3) 0.021
Calm 20 (71.4) 24 (88.9) 20 (66.7) 27 (90.0)
Agitated 8 (28.6) 1 (3.7) 10 (33.3) 2 (6.7)
After 30 min Sedated 0.196 0 (0.0) 0 (0.0) 0.193 0 (0.0) 0 (0.0) 0.097
Calm 24 (82.1) 26 (96.3) 26 (86.7) 29 (96.7)
Agitated 5 (17.9) 1 (3.7) 4 (13.3) 1 (3.3)
Values are the number (%). Patients were categorized as agitated, RSAS 5 to 7; calm, RSAS 4; and sedated, RSAS 1 to 3 while in the recovery room postoperatively.
Group SN, inhalation anaesthesia using sevoflurane and normal saline administered as a control; Group SD, inhalation anaesthesia using sevoflurane and adjuvant
dexmedetomidine; Group TN, TIVA using propofol and remifentanil and normal saline administered as a control; Group TD, TIVA using propofol and remifentanil,
and adjuvant dexmedetomidine; TIVA total intravenous anaesthesia, RSAS Riker’s sedation-agitation scale
Fig. 4 Incidence of emergence agitation and dangerous emergence agitation in the recovery room 30 min after arrival. Group SN, inhalation
anaesthesia using sevoflurane and normal saline administered as a control; Group SD, inhalation anaesthesia using sevoflurane and adjuvant
dexmedetomidine; Group TN, TIVA using propofol and remifentanil and normal saline administered as a control; Group TD, TIVA using propofol
and remifentanil, and adjuvant dexmedetomidine; TIVA, total intravenous administration; EA, emergence agitation. Emergence agitation was
defined as a Riker’s sedation-agitation scale greater than 5, and dangerous EA was defined as a score greater than 7
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there was no significant differences between group
TN and TD. The incidence of PONV differed only
according to the anaesthetic method (Table 3). There
were no significant differences between the SN and
SD groups (P = 0.646), and between the TN and TD
groups (P = 0.640). There were no differences in the dur-
ation of recovery room stay between the groups (Table 3).
Discussion
In this study, dexmedetomidine significantly decreased
the RSAS score, the incidence of emergence agitation,
and the patients in the dexmedetomidine groups
remained calm state after surgery more frequently than
did the patients in the control groups. These results sug-
gest that dexmedetomidine (0.4 μg kg−1 hr−1) can be
used as an effective adjuvant drug intraoperatively to
ensure a smooth recovery after orthopaedic surgery in
elderly patients.
During emergence from anaesthesia, elderly patients may
experience psychological dysfunction such as delirium, agi-
tation, confusion, or cognitive dysfunction, which is associ-
ated with postoperative morbidity [3, 10, 11]. Although the
mechanism of postoperative psychological dysfunction is
unclear and multifactorial, postoperative pain [12], hypoxia
[13], opioid use [14], and anaesthetic technique [15] may
encourage the development of postoperative delirium. Eld-
erly patients who are undergoing orthopaedic surgery are at
a particularly high risk [4].
Recent studies showed that dexmedetomidine decreased
emergence agitation in children [5], and decreased postop-
erative delirium after cardiac surgery [16] and nasal surgery
[6]. Dexmedetomidine is a highly selective α2-receptor
agonist that has a sedative effect [17]. It may also affect the
Fig. 5 Hemodynamic changes during infusion of adjuvant drugs and during anaesthetic emergence. a Mean arterial pressure and (b) heart rate
measured. Pre-infusion, before infusion of adjuvant drugs; In-10 min, 10 min after infusion of adjuvant drugs; In-30 min, 30 min after infusion of
adjuvant drugs; RR, at arrival to recovery room;, RR-15 min, 15 min after arrival to recovery room; RR-30 min, 30 min after arrival to recovery room.
Group SN, inhalation anaesthesia using sevoflurane and normal saline administered as a control; Group SD, inhalation anaesthesia using sevoflurane
and adjuvant dexmedetomidine; Group TN, TIVA using propofol and remifentanil and normal saline administered as a control; Group TD, TIVA using
propofol and remifentanil, and adjuvant dexmedetomidine. *P < 0.05 compared with the SN group. †P < 0.05 compared with the TN group
















Maximum RSAS <0.001 5.4 (1.0) 4.1 (0.3) <0.001 4.9 (1.2) 4.2 (0.7) 0.041
VAS 0.020 6.6 (1.9) 5.3 (1.9) 0.011 5.7 (2.1) 5.1 (1.6) 0.246
PONV 0.003 11 (39.3) 9 (34.6) 0.654 3 (10.0) 2 (6.7) 0.732
Duration of recovery room stay (min) 0.567 42.1 (6.7) 41.5 (6.1) 0.534 42.0 (7.3) 43.2 (7.3) 0.276
Values are the mean (SD) or number (%). Group SN, inhalation anaesthesia using sevoflurane and normal saline administered as a control; Group SD, inhalation
anaesthesia using sevoflurane and adjuvant dexmedetomidine; Group TN, TIVA using propofol and remifentanil and normal saline administered as a control;
Group TD, TIVA using propofol and remifentanil, and adjuvant dexmedetomidine; RSAS Riker’s sedation-agitation scale, VAS visual analogue score, PONV postoperative
nausea and vomiting
Kim et al. BMC Anesthesiology  (2015) 15:139 Page 8 of 11
presynaptic noradrenergic transmission, which may de-
crease the potential causative factors of delirium [16, 18].
Dexmedetomidine also provides analgesia without causing
significant respiratory depression [19]. It may help reduce
opioid use while protecting against hypoxia due to
hypoventilation in during anaesthetic recovery, and conse-
quently may reduce the development of delirium. However,
the sedative effects of dexmedetomidine may also influence
recovery after anaesthesia when used as an adjuvant drug.
It has been shown that adjuvant dexmedetomidine
during general anaesthesia decreases the sevoflurane or
propofol required to maintain an adequate depth of an-
aesthesia [20–22]. Consistent with a study by Patel [20],
in the present study, the end-tidal concentration of sevo-
flurane after 60 min was lower in the SD group (1.20 ±
0.38) compared to the SN group (1.68 ± 0.48, P < 0.001).
According to the previous studies, dexmedetomdine de-
creased effective end-tidal concentration of isoflurane
and effective plasma concentration of propofol for abol-
ishing motor or verbal responses [23]. In case of motor
response, end-tidal isoflurane concentration at which
50 % of subjects responded was decreased from 1.048 to
0.722 % when plasma concentration of dexmedetomi-
dine was maintained as 0.3 ng/ml. According to the
pharmacokinetic simulation using pharmacokinetic pro-
files of Korean subjects [24], plasma concentration of
demedetomidine reached 0.1 ng/ml at about 10 min
after continuous infusion (0.4 μg kg−1 hr−1). At this
point, end-tidal concentration of sevoflurane started to
became lower in the group SD than group SN (1.29 in
group SD vs. 1.76 in group SN) in this study. Although
calculated plasma concentration of demedetomidine is
less than that of previous study, the subjects of this
study were elderly, not healthy adult. Thus, we thought
low dose infusion of dexmedetomidine (01 ng/ml of
plasma concentration) could be effective to reduce the
end-tidal concentration of sevoflurane during anaesthe-
sia. According to a study conducted by Le Guen, when
dexmedetomidine was administered, the propofol dosage
decreased approximately 29 % during anaesthetic main-
tenance; however, there was no significant difference in
the remifentanil dosage [22]. These results are consistent
with our findings. The effect site concentration of pro-
pofol was also lower in the TD group compared to the
TN group after 10 min (mean 3.11 vs. 2.26, respectively,
P = 0.026), but the effect Ce of remifentanil was not sig-
nificantly different (P = 0.974). Moreover, there were no
significant differences in the postoperative VAS scores.
This finding may be because dexmedetomidine produces
analgesia through the α2-receptor, which is less effective
than opioids receptors [25]. Dexmedetomidine acts pri-
marily as a sedative rather than an analgesic [22].
The recovery time increased in groups using TIVA
compared to those using sevoflurane. Propofol appears
to have a prolonged effect in the elderly because of its
lipid solubility and the proportion of fat in the total body
weight in elderly patients [8]. A significant difference in
the recovery time between the dexmedetomidine and
control groups was only observed prior to eye opening
and extubation between the SN and SD groups. How-
ever, there was a remarkable difference observed in a
previous study conducted by Ohtani and others [7].
They reported that dexmedetomidine delayed the emer-
gence from propofol anaesthesia and suspected that the
pharmacodynamic interaction between dexmedetomi-
dine and propofol may have delayed emergence from an-
aesthesia [7]. In this study, we adjusted the Ce of
propofol according to the BIS score; thus, dexmedetomi-
dine decreased the administered propofol. Consequently,
there were no significant differences in the recovery time
between the TN and TD groups.
Kim and others reported that the intraoperative infu-
sion of dexmedetomidine provided smooth emergence
and decreased agitation after nasal surgery [6], which
agrees with our present results. In the current study,
dexmedetomidine decreased emergence agitation (75 %
in the SN group vs. 11.1 % in the SD group, P < 0.001;
43.3 % in the TN group vs. 10.1 % in the TD group, P =
0.004), but there were no significant difference in the in-
cidence of dangerous emergence agitation. When pa-
tients arrived at the recovery room after surgery, more
patients remained in a calm state when dexmedetomi-
dine was administered (25.0 % in the SN group vs.
40.7 % in the SD group, P < 0.001; 36.7 % in the TN
group vs. 53.3 % in the TD group, P = 0.013). However,
none of the patients were sedated after 30 min. Though
it remains uncertain, the sedative property of dexmede-
tomidine and the pharmacodynamic interaction between
dexmedetomidine and anaesthetics may affect the seda-
tive state after anaesthetic recovery [7, 26]. Further
evaluation of the interaction between adjuvant dexmede-
tomidine and anaesthetics is needed.
Similarly, a study conducted by Kim and others
reported that the postoperative heart rate decreased in
patients administered dexmedetomidine [6]; however,
there were no statistical differences in the MAP between
the experimental and control groups. Potentially, the
timing of measurement may have generated these differ-
ent outcomes. Kim and others measured the MAP and
HR when the surgery was complete and after extubation
[6]. By contrast, we measured these parameters later
when the patients arrived in the recovery room. Regard-
less, the ability of dexmedetomidine to control the
increase in heart rate during recovery is attractive.
There are several limitations in this study. First, the
gender distribution is uneven. Although gender has no
known effect on the development of emergence delirium
[4], it may potentially affect the recovery time and other
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characteristics. Second, we did not evaluate the long-
term effect of dexmedetomidine on postoperative delir-
ium. We focused solely on recovery characteristics and
smooth emergence after anaesthesia with dexmedetomi-
dine administration. However, postoperative delirium
can develop up to 3 days postoperatively [4]; therefore,
further evaluation employing long-term follow up is
needed. Third, we did not administer a loading dose of
dexmedetomidine. When using dexmedetomidine to in-
duce sedation, an initial loading dose is required, but
this protocol is associated with sudden hemodynamic
changes [27]. When we contacted with IRB and KFDA
for approval of the protocol of this study, the best con-
cern was that the dexmedetomidine is not an anaesthetic
drug and there is no guarantee of safety when adminis-
tered as conventional method with other anaesthetic
drugs. However, adjuvant dexmedetomidine adminis-
tered intraoperatively without an initial loading effect-
ively reduced emergence agitation according to a
previous study [6]. In addition, the primary outcome was
emergence agitation and smooth emergence from anaes-
thesia, not the hemodynamic response during anaesthe-
sia. Thus, we used the protocol which does not used
loading dose of dexmedetomidine and slow rate of infu-
sion (0.4 μg kg−1 hr−1) as employed previously [6].
Fourth, we did not count the use of haemodynamic
drugs, which was methodological error.
Conclusions
The administration of dexmedetomidine (0.4 μg kg−1 hr−1)
decreased the emergence agitation after orthopaedic sur-
gery in elderly patients. These results may support the adju-
vant use of dexmedetomidine for smooth emergence from
anaesthesia and further evaluation of the potential of dex-
medetomidine to reduce long-term cognitive dysfunction
in elderly patients.
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